

Cover Story
By Matthew Bin Han Ong
The vast majority of patients with prostate cancer in the United States don't receive androgen deprivation therapy injections on time. Up to 84% of injections are delayed for patients on a 28-day schedule, according to an authoritative study published in the The Journal of Urology.
In Brief
Clinical Roundup
Drugs & Targets


Trending Stories
- Christine Lovly to lead City of Hope’s new national thoracic oncology program
- FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence - Tidmarsh is out, Pazdur is in: FDA’s CDER under new leadership
- Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA
- Smoldering multiple myeloma: Rethinking the waiting game
- Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director


















